Skip to contentS
Skye Bioscience, Inc.
S
SKYESkye Bioscience, Inc. Released Aug 5, 2021, after the close
10-Q filed Aug 6, 2021, 37 days after period end · 0001628280-21-015972
Q2 2021 · 10-Q
Revenue—
Net Income-$2.02M-$2.02MN/M vs Q2 2020N/M vs Q1 2021 No earnings release is on file for this quarter. Its figures came with the 10-Q.
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Skye Bioscience, Inc. · CIK 1516551 · Engraved from SEC EDGAR
EPS Diluted-$0.01-$0.01N/M vs Q2 2020N/M vs Q1 2021 Operating Income-$1,829,674N/M Operating Cash Flowderived-$1,671,401N/M Free Cash Flowderived-$1,670,875N/M Filing lag
ended Jun 30, 2021 · filed Aug 6, 2021 · 37 d after period end